Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
Iain C Macdougall, William E Strauss, Naomi V Dahl, Kristine Bernard, Zhu Li, Iain C Macdougall, William E Strauss, Naomi V Dahl, Kristine Bernard, Zhu Li
Abstract
Background: Patients with chronic kidney disease (CKD) undergoing dialysis often require intravenous iron for iron deficiency anemia (IDA).
Materials and methods: The Ferumoxytol for Anemia of CKD Trial (FACT), a randomized, multicenter, open-label, phase 4 study, compared the long-term safety and efficacy of ferumoxytol with iron sucrose for the treatment of IDA in patients with CKD undergoing hemodialysis. Patients with IDA and CKD undergoing hemodialysis were randomized 2:1 to ferumoxytol 1.02 g (2 × 510 mg) or iron sucrose 1.0 g (10 × 100 mg) for a 5-week treatment period (TP). Over 11 months, patients underwent additional 5-week TPs whenever IDA (hemoglobin < 11.5 g/dL and transferrin saturation < 30%) was detected. The primary efficacy endpoint was mean change in hemoglobin from baseline to week 5 for each TP. Adverse events were recorded during the study.
Results: Overall, 293 patients received ferumoxytol (n = 196) or iron sucrose (n = 97). Ferumoxytol was noninferior to iron sucrose regarding hemoglobin change from baseline to week 5. The mean change in hemoglobin in the ferumoxytol and iron sucrose groups was 0.5 and 0.4 g/dL, respectively, in TP 1 (least-squares mean difference, 0.13; 95% confidence interval, -0.11 to 0.36) and 0.6 and 0.3 g/dL, respectively, in TP 2 (0.30; 0.06 - 0.55). Treatment-related and serious adverse events were similar in both groups; no new safety signals emerged.
Conclusion: Long-term administration of ferumoxytol has noninferior efficacy and a similar safety profile to iron sucrose when used to treat IDA in patients with CKD undergoing hemodialysis. .
Figures
References
- Macdougall IC Geisser P Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis. 2013; 7: 9–22.
- Babitt JL Lin HY Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23: 1631–1634.
- Charytan DM Pai AB Chan CT Coyne DW Hung AM Kovesdy CP Fishbane S Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015; 26: 1238–1247.
- Bailie GR Larkina M Goodkin DA Li Y Pisoni RL Bieber B Mason N Tong L Locatelli F Marshall MR Inaba M Robinson BM Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013; 28: 2570–2579.
- KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2: 279–335.
- Anirban G Kohli HS Jha V Gupta KL Sakhuja V The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008; 30: 629–638.
- Besarab A Amin N Ahsan M Vogel SE Zazuwa G Frinak S Zazra JJ Anandan JV Gupta A Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000; 11: 530–538.
- Charytan C Bernardo MV Koch TA Butcher A Morris D Bregman DB Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013; 28: 953–964.
- Goldstein SL Morris D Warady BA Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Am J Kidney Dis. 2013; 61: 588–597.
- Kosch M Bahner U Bettger H Matzkies F Teschner M Schaefer RM A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001; 16: 1239–1244.
- Macdougall IC Strauss WE McLaughlin J Li Z Dellanna F Hertel J A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014; 9: 705–712.
- Sav T Tokgoz B Sipahioglu MH Deveci M Sari I Oymak O Utas C Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007; 29: 423–426.
- Sheashaa H El-Husseini A Sabry A Hassan N Salem A Khalil A El-Agroudy A Sobh M Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract. 2005; 99: c97–c101.
- Warady BA Zobrist RH Wu J Finan E Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol. 2005; 20: 1320–1327.
- Macdougall IC Dahl NV Bernard K Li Z Batycky A Strauss WE The Ferumoxytol for Anemia of CKD Trial (FACT) – a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. BMC Nephrol. 2017; 18: 117.
- Storey P Lim RP Chandarana H Rosenkrantz AB Kim D Stoffel DR Lee VS MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol. 2012; 47: 717–724.
- Provenzano R Schiller B Rao M Coyne D Brenner L Pereira BJ Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4: 386–393.
- Fishbane S Mathew A Vaziri ND Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014; 29: 255–259.
- Van Buren P Velez RL Vaziri ND Zhou XJ Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol. 2012; 44: 499–507.
Source: PubMed